Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Translational Research Office (TRO) would like to bring to your attention the next rounds of calls that are now OPEN/OPENING SOON for the MRC Developmental Pathway Funding Scheme.

Outline Stage

Opens: 12 February 2021

Closes: 24 March 2021


Full Stage

Opened: 3 February 2021

Closes: 10 March 2021


The DPFS scheme is the MRC's key Translational Research Strategy and supports the translation of fundamental discoveries towards the benefit to human health. The remit of the DPFS scheme includes funding: the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, and repurposing existing therapies. All disease areas (including global health) and modalities of intervention are eligible to apply including: small molecules, peptides, antibodies, vaccines, regenerative medicine, cell and gene therapy, devices, surgical techniques and psychological approaches. 

The TRO's mission is to support and facilitate the translation of Oxford's emerging basic, biomedical and clinical research towards therapies, techniques and medical products with therapeutic value. 

If you are interested in applying to this call, the TRO can support you in drafting your application. Please contact the TRO as soon as possible to get the best out of our support service, ideally before 17 Feb for full applications and 3 Mar for outline applications.